-

1&1 Drilisch's 4th MNO Entry in Germany, 2021 Case Study Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "1&1 Drilisch's 4th MNO Entry in Germany - Will it work?" company profile has been added to ResearchAndMarkets.com's offering.

1&1 Drillisch's MVNO business in Germany would become unprofitable when 5G goes mainstream, so investing in spectrum was 1&1 Drillisch's only choice to keep its business afloat. 1&1 Drillisch's 4th MNO business case will be positive if BNetzA intervenes and mandates competitive national data roaming rates.

Highlights

  • Why 1&1 Drillisch decided to invest in spectrum?
  • What was wrong with 1&1 Drillisch's MVNO business model?
  • How much will 1&1 Drillisch need to invest to build a mobile network that will put it on a similar footing with the other 3 MNOs?
  • How much more and what type of spectrum will 1&1 Drillisch need to acquire and by when?
  • When will 1&1 Drillisch's 4th MNO operation in Germany turn cash flow positive?
  • How long will 1&1 Drillisch's MNO business case payback period be?
  • Can 1&1 Drillisch run a profitable 4th MNO business case without securing competitive national data roaming rates?
  • What is the minimum subscriber share and ARPS level required to break even in a reasonable period?
  • Can 1&1 Drillisch break even with smartphone subscribers only?
  • Should 1&1 Drillisch pursue fixed-to-mobile broadband substitution?
  • How many 4G/5G wireless broadband subscribers can 1&1 Drillisch acquire and how much more spectrum will it need?
  • Is 1&1 Drillisch's incremental 4th MNO business case positive?
  • Should Bundesnetzagentur intervene and mandate competitive national data roaming rates?
  • How low should a competitive national data roaming rate be when first introduced and how fast should the rate decline?

Key Topics Covered:

1 Study context and methodology

1.1 Context

1.2 Methodology

2 Executive summary

3 The German mobile market: From 4 down to 3 mobile network operators and soon back to 4?

4 Market model projections

4.1 Mobile subscribers: smartphones, prepaid, mobile broadband and wireless broadband subscribers

4.2 Average Revenue Per Subscriber (ARPS)

4.3 Mobile service revenue

4.4 Average mobile data usage per subscriber and mobile data volume

5 1&1 Drillisch's baseline MNO business case presumptions and outputs

5.1 Current and future spectrum holdings

5.2 Mobile network rollout and 1&1 Drillisch traffic in own versus in national roaming partner's network

5.3 Purchases used in production including business-critical national data roaming costs

5.4 Operating expenses

5.5 Capital expenditure and spectrum fees

5.6 Gross profit, EBITDA and Cash Flow

5.7 Cumulative cash flow and payback period

6 1&1 Drillisch's business case analysis & sensitivity

6.1 1&1 Drillisch's payback period as a function of projected market share and ARPS.

6.2 1&1 Drillisch's business case with and without 4G/5G wireless home broadband subscribers

6.3 Impact of 1&1 Drillisch's spectrum holdings on mobile network capacity utilization and national roaming costs

6.4 1&1 Drillisch's payback period as a function of national data roaming rate glide path

6.5 1&1 Drillisch 4th MNO vs. MVNO business case as a function of wholesale access data rate glide paths

6.6 1&1 Drillisch's incremental 4th MNO business case

6.7 1&1 Drillisch's 4th MNO German business case versus Iliad's 4th MNO Italian business case

Companies Mentioned

  • 1&1 Drillisch
  • Deutsche Telekom
  • Freenet
  • Iliad
  • T-Mobile
  • Telefonica O2
  • Vodafone

For more information about this company profile visit https://www.researchandmarkets.com/r/m3q2pz

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom